Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
In Vitro Antifungal Activity of Luliconazole, Efinaconazole, and Nine Comparators Against Aspergillus and Candida Strains Isolated From Otomycosis Publisher



Shokoohi G1 ; Rouhi R2 ; Etehadnezhad M1 ; Ahmadi B3 ; Javidnia J4 ; Nouripoursisakht S5 ; Hooshmand F6 ; Rezaeimatehkolaei A7 ; Tabatabaeifar SN8 ; Ansari S9
Authors

Source: Jundishapur Journal of Microbiology Published:2021


Abstract

Background: Aspergillus and Candida species are the most commonly identified fungal pathogens in otomycosis. However, we usually encounter some difficulties in its treatment because many patients show resistance to antifungal agents and present a high recurrence rate. Objectives: The current research was conducted to compare the in vitro activities of luliconazole (LUL), and efinaconazole (EFN) and the nine comparators on Aspergillus and Candida strains isolated from otomycosis. Methods: The in vitro activities of nine common antifungal drugs (amphotericin B (AMB), voriconazole (VRC), fluconazole (FLU), itraconazole (ITC), ketoconazole (KTO), clotrimazole (CLO), nystatin (NYS), terbinafine (TRB), and caspofungin (CAS)) and two novel new azoles (LUL and EFN) against of 108 clinical isolates of Aspergillus and Candida species obtained from otomycosis were assessed according to the CLSI broth microdilution document. Results: The LUL and EFN had the geometric mean minimum inhibitory concentrations (GM MICs) of 0.098 and 0.109 µg/mL against all Aspergillus strains, respectively. Furthermore, the GM MICs of all Candida isolates for LUL, EFN, CAS, CLO, VRC, AMB, ITC, KTO, FLU, NYS, and TRB were calculated to be 0.133, 0.144, 0.194, 0.219, 0.475, 0.537, 0.655, 1.277, 4.905, 9.372, and 13.592 µg/mL, respectively. Additionally, 6 (35.29%), 2 (11.7%), and 1 (5.88%) Candida isolates were resistant to FLU, CAS, and VRC, respectively. Conclusions: As the findings indicated, LUL and EFN showed the lowest GM MIC values against the examined species. Accordingly, these novel imidazole and triazole antifungal agents can be regarded as proper candidates for the treatment of otomycosis caused by Aspergillus and Candida strains. © 2021, Author(s).
Related Docs
View other Related Docs
1. In Vitro Antifungal Susceptibility Profile of Iranian Fusarium Isolates: Emphasising on the Potent Inhibitory Effect of Efinaconazole Compared to Other Drugs, Mycoses (2023)
2. Species Identification and in Vitro Antifungal Susceptibility Testing of Aspergillus Section Nigri Strains Isolated From Otomycosis Patients, Journal de Mycologie Medicale (2018)
3. In Vitro Activities of Luliconazole, Lanoconazole, and Efinaconazole Compared With Those of Five Antifungal Drugs Against Melanized Fungi and Relatives, Antimicrobial Agents and Chemotherapy (2017)
Experts (# of related papers)
View all Related Experts
Roshanak Daei Ghazvini (4)
Sadegh Khodavaisy (4)
Other Related Docs
4. Otomycosis: A Systematic Review and Meta-Analysis of Prevalence and Causative Agents in the Era of Molecular Diagnostics, BMC Infectious Diseases (2025)
5. Comparison of in Vitro Antifungal Activity of Novel Triazoles With Available Antifungal Agents Against Dermatophyte Species Caused Tinea Pedis, Journal de Mycologie Medicale (2020)
6. Multicenter Study of Susceptibility of Aspergillus Species Isolated From Iranian University Hospitals to Seven Antifungal Agents, Microbiology Spectrum (2022)
7. Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole Against a Collection of Azole-Resistant and -Susceptible Aspergillus Fumigatus Strains, Antimicrobial Agents and Chemotherapy (2016)
8. Isolation, Characterization, and Antifungal Sensitivity Pattern of Fungal Species With Potential Resistance to Antifungal Drugs in Patients With Otomycosis, Archives of Clinical Infectious Diseases (2022)
9. In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex, Mycopathologia (2016)
10. First Molecular Report of Causative Agent of Otomycosis Due to Aspergillus Luchuensis, Journal of Wound Care (2021)
11. Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators Against Molecularly Characterized Fusarium Species, Antimicrobial Agents and Chemotherapy (2018)
12. Otomycosis in Western Iran: Clinical and Mycological Aspects, Archives of Clinical Infectious Diseases (2017)
13. Comparison of in Vitro Activities of Newer Triazoles and Classic Antifungal Agents Against Dermatophyte Species Isolated From Iranian University Hospitals: A Multi-Central Study, Annals of Clinical Microbiology and Antimicrobials (2023)
14. Comparison of Acidifying Agents and Clotrimazole for Treatment of Otomycosis: A Comprehensive One-Way Mini-Review, Current Medical Mycology (2023)
15. Trends in the Prevalence of Amphotericin B-Resistance (Ambr) Among Clinical Isolates of Aspergillus Species, Journal of Medical Mycology (2022)
16. Isolation, Characterization, and Antifungal Sensitivity Pattern of Candida Species Causing Otomycosis, Acta Medica Iranica (2023)
17. Clinical, Epidemiological, and Mycological Features of Patients With Candidemia: Experience in Two Tertiary Referral Centers in Iran, Current Medical Mycology (2022)
18. Ocular Fungi: Molecular Identification and Antifungal Susceptibility Pattern to Azoles, Jundishapur Journal of Microbiology (2020)
19. Species Distribution and Antifungal Susceptibility Profile of Candida Isolates From Blood and Other Normally Sterile Foci From Pediatric Icu Patients in Tehran, Iran, Medical Mycology (2020)
20. Antifungal Susceptibility Testing of Candida Species Isolated From the Immunocompromised Patients Admitted to Ten University Hospitals in Iran: Comparison of Colonizing and Infecting Isolates, BMC Infectious Diseases (2017)